📊 CRBP Key Takeaways
Investment Thesis
Corbus Pharmaceuticals is in severe financial distress with minimal revenue generation ($2.8M) unable to offset massive operating losses (-$85.3M). The company is burning cash at an unsustainable rate (-$64.5M operating cash flow) with no clear path to profitability, representing substantial fundamental risk despite adequate current liquidity.
CRBP Strengths
- Strong balance sheet with no long-term debt and solid equity position of $147.5M
- Excellent liquidity position with current ratio of 8.07x providing runway for operations
- Low liability burden at $20.7M relative to total assets of $168.2M
CRBP Risks
- Catastrophic operating losses of -$85.3M against minimal $2.8M revenue indicates business model failure or pre-commercialization crisis
- Severe cash burn of -$64.5M annually will deplete equity rapidly; at current burn rate cash runway is approximately 5 months without additional capital raises
- Negative gross margin (N/A reported) and inability to achieve operating leverage suggests fundamental unit economics problems or failed drug development programs
Key Metrics to Watch
- Quarterly revenue growth and pipeline commercialization progress
- Monthly cash burn rate and operating cash flow trends
- R&D spending efficiency and clinical trial milestone achievement
CRBP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.07x current ratio provides a solid financial cushion.
CRBP Profitability Ratios
CRBP vs Healthcare Sector
How Corbus Pharmaceuticals Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRBP Balance Sheet & Liquidity
CRBP 5-Year Financial Trend
5-Year Trend Summary: Corbus Pharmaceuticals Holdings, Inc.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-3.68 indicates the company is currently unprofitable.
CRBP Growth Metrics (YoY)
CRBP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$2.2M | $-0.02 |
| Q2 2022 | $136.6K | -$13.2M | $-0.11 |
| Q1 2022 | N/A | -$9.4M | $-0.08 |
| Q3 2021 | $97.3K | -$2.2M | $-0.02 |
| Q2 2021 | $136.6K | -$17.1M | $-0.15 |
| Q1 2021 | $647.8K | -$16.1M | N/A |
| Q3 2020 | $1.2M | -$20.8M | N/A |
| Q2 2020 | $286.3K | $2.2M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRBP Capital Allocation
CRBP SEC Filings
Access official SEC EDGAR filings for Corbus Pharmaceuticals Holdings, Inc. (CIK: 0001595097)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRBP
What is the AI rating for CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRBP's key strengths?
Strong balance sheet with no long-term debt and solid equity position of $147.5M. Excellent liquidity position with current ratio of 8.07x providing runway for operations.
What are the risks of investing in CRBP?
Catastrophic operating losses of -$85.3M against minimal $2.8M revenue indicates business model failure or pre-commercialization crisis. Severe cash burn of -$64.5M annually will deplete equity rapidly; at current burn rate cash runway is approximately 5 months without additional capital raises.
What is CRBP's revenue and growth?
Corbus Pharmaceuticals Holdings, Inc. reported revenue of $2.8M.
Does CRBP pay dividends?
Corbus Pharmaceuticals Holdings, Inc. does not currently pay dividends.
Where can I find CRBP SEC filings?
Official SEC filings for Corbus Pharmaceuticals Holdings, Inc. (CIK: 0001595097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRBP's EPS?
Corbus Pharmaceuticals Holdings, Inc. has a diluted EPS of $-5.90.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.